Literature DB >> 7097564

Oxidation of (R)- and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity.

C von Bahr, J Hermansson, M Lind.   

Abstract

Propranolol is an adrenergic beta receptor antagonist whose kinetics is complicated by dose-dependency, formation of active metabolites and stereoselective availability. To get some insight of the possible metabolic factors behind this, we have incubated the two optical isomers (R)- and (S)-propranolol with human and dog liver microsomes. Propranolol and its oxidized metabolites 4-hydroxypropranolol (4-OH-P) and N-desisopropylpropranolol (nor-P) were analyzed using high-performance liquid chromatography and fluorometric detection. The oxidation rates varied markedly between human livers. Most of metabolized propranolol was recovered as 4-OH-P and nor-P and more propranolol was oxidized than glucuronidated. Formation rates of 4-OH-P and nor-P were approximately half-maximal at propranolol concentrations than can occur in the liver in vivo. The ratio between formation of these metabolites varied markedly between livers. Human livers formed 4-OH-P and nor-P most rapidly from (R)-propranolol, whereas dog livers formed 4-OH-P most rapidly from (S)-propranolol. We suggest that the interindividual differences in the capacity of the livers to metabolize propranolol largely should contribute to the kinetic variations observed between patients in vivo and the gradual saturation of 4-hydroxylation and N-desisopropylation of propranolol are likely to contribute to the dose-dependent kinetics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7097564

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

2.  The effect of propranolol on exercise induced tachycardia is determined by plasma concentration and the density of adrenergic receptors on leukocytes.

Authors:  K Tawara; E Steiner; C von Bahr
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.

Authors:  S V Otton; E M Gillam; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

4.  Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

Authors:  K Yoshimoto; H Echizen; K Chiba; M Tani; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

5.  Stereoselective binding of propranolol enantiomers to human alpha 1-acid glycoprotein and human plasma.

Authors:  F Albani; R Riva; M Contin; A Baruzzi
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

6.  Stereoselective ring oxidation of propranolol in man.

Authors:  T Walle; U K Walle; M J Wilson; T C Fagan; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

7.  Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation.

Authors:  N Bodor; L Prokai
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

8.  Nonlinear accumulation of propranolol enantiomers.

Authors:  R L Lalonde; M B Bottorff; R J Straka; D M Tenero; J A Pieper; I W Wainer
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.